GlassScriptPhysician profile
Severine Kako
NPI 1629605944
$35,991.85
in general payments reported to CMS, 2019-2025
25 companies · $2,466 in 2025
The $2,466 reported for 2025 was more than what 76% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $158 · 2022: $312 · 2023: $539 · 2024: $33K · 2025: $2,466.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $30K · Travel and Lodging: $2,857 · Food and Beverage: $2,665.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $30,000.00 |
| Travel and Lodging | $2,857.45 |
| Food and Beverage | $2,665.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $23,530.37 | 2024-2025 | Activa PC, Percept PC Brainsense |
| Boston Scientific Corporation | $10,650.61 | 2024-2025 | Vercise |
| E.R. Squibb & Sons, L.L.C. | $338.43 | 2022-2023 | Zeposia |
| Emd Serono, INC. | $281.57 | 2022-2025 | Mavenclad |
| Novartis Pharmaceuticals Corporation | $160.48 | 2024 | |
| Revance Therapeutics, INC. | $120.94 | 2024 | Daxxify |
| Alexion Pharmaceuticals, INC. | $104.51 | 2021-2024 | Ultomiris |
| Abbott Laboratories | $101.58 | 2025 | Infinity |
| Ucb, INC. | $93.82 | 2023-2025 | Briviact |
| Biogen, INC. | $93.31 | 2021 | |
| Averitas Pharma INC. | $91.84 | 2023-2025 | Qutenza |
| Astrazeneca Pharmaceuticals LP | $78.62 | 2021-2024 | Wainua, Andexxa |
| Pfizer INC. | $58.93 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $46.46 | 2022-2023 | Gammagard |
| Teva Pharmaceuticals USA, INC. | $43.55 | 2025 | Austedo Xr |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $36.06 | 2022 | |
| Merz Pharmaceuticals, LLC | $26.17 | 2024 | Xeomin, Inbrija |
| Alnylam Pharmaceuticals INC. | $18.60 | 2025 | Onpattro |
| Genzyme Corporation | $17.84 | 2022 | |
| Lilly USA, LLC | $17.38 | 2024 | Amyvid |
| Jazz Pharmaceuticals INC. | $16.82 | 2024 | |
| Amneal Pharmaceuticals LLC | $16.76 | 2022 | |
| Celgene Corporation | $16.60 | 2021 | |
| Horizon Therapeutics Plc | $15.90 | 2022 | |
| Abbvie INC. | $14.70 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Severine Kako listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.